(0.06%) 5 387.00 points
(0.07%) 38 820 points
(0.05%) 19 252 points
(0.98%) $78.66
(-1.31%) $3.09
(0.20%) $2 331.20
(0.89%) $29.49
(0.11%) $960.00
(-0.06%) $0.930
(-0.28%) $10.67
(-0.12%) $0.784
(0.01%) $89.25
Live Chart Being Loaded With Signals
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases...
Stats | |
---|---|
本日の出来高 | 7 961 |
平均出来高 | 674 911 |
時価総額 | 11.39M |
EPS | $-141.14 ( Q1 | 2024-05-13 ) |
次の収益日 | ( $-0.190 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.220 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.170 (1.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Truex Samantha | Buy | 0 | |
2024-03-27 | Goldman Jonathan | Buy | 0 | |
2024-03-28 | Kantoff Aaron | Buy | 0 | |
2023-12-20 | Persson Magnus | Buy | 3 334 | Stock Option (Right to Buy) |
2023-12-20 | Almenoff June Sherie | Buy | 3 334 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-64.98 |
Last 97 transactions |
Buy: 5 555 925 | Sell: 5 291 542 |
Avalo Therapeutics, Inc. 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Avalo Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $1.92M |
総利益: | $640 000 (33.26 %) |
EPS: | $-113.58 |
FY | 2023 |
収益: | $1.92M |
総利益: | $640 000 (33.26 %) |
EPS: | $-113.58 |
FY | 2022 |
収益: | $18.05M |
総利益: | $14.62M (80.98 %) |
EPS: | $-1 062.68 |
FY | 2021 |
収益: | $5.40M |
総利益: | $3.91M (72.38 %) |
EPS: | $-9.96 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn\'s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still\'s disease, including adult-onset still\'s disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。